March 13 (Reuters) - Correvio Pharma Corp CORV.TO :
* CORREVIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS
* COMPANY ON TRACK TO RESUBMIT BRINAVESS NDA IN Q2 2019
* Q4 LOSS PER SHARE $0.18
* Q4 REVENUE $8.9 MILLION VERSUS $7.0 MILLION
* CORREVIO PHARMA - MARK H.N. CORRIGAN HAS BEEN NAMED CORREVIO'S NEXT CHIEF EXECUTIVE OFFICER, EFFECTIVE MARCH 14, 2019
* CORREVIO PHARMA - JUSTIN RENZ, CHIEF FINANCIAL OFFICER OF CORREVIO, ASSUMED THE RESPONSIBILITIES OF PRESIDENT